-
1
-
-
33846181370
-
Sunitinib vs. interferon-α in metastatic renal-cell carcinoma
-
Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib vs. interferon-α in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
-
(2007)
N Engl J Med
, vol.356
, pp. 115-124
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
-
2
-
-
33846148701
-
Sorafenib in advanced clear-cell renal-cell carcinoma
-
Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
-
(2007)
N Engl J Med
, vol.356
, pp. 125-134
-
-
Escudier, B.1
Eisen, T.2
Stadler, W.M.3
-
3
-
-
0035312747
-
Regulation of translation initiation by FRAP/mTOR
-
Gingras A.C., Raught B., and Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 15 (2001) 807-826
-
(2001)
Genes Dev
, vol.15
, pp. 807-826
-
-
Gingras, A.C.1
Raught, B.2
Sonenberg, N.3
-
4
-
-
0028360374
-
A mammalian protein targeted by G1-arresting rapamycin-receptor complex
-
Brown E.J., Albers M.W., Shin T.B., et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369 (1994) 756-758
-
(1994)
Nature
, vol.369
, pp. 756-758
-
-
Brown, E.J.1
Albers, M.W.2
Shin, T.B.3
-
6
-
-
0037108750
-
Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling
-
Tee R., Fingar D.C., Manning B.D., et al. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci USA 99 (2002) 13571-13576
-
(2002)
Proc Natl Acad Sci USA
, vol.99
, pp. 13571-13576
-
-
Tee, R.1
Fingar, D.C.2
Manning, B.D.3
-
7
-
-
0036713778
-
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling
-
Inoki K., Li Y., Zhu T., et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling. Nat Cell Biol 4 (2002) 648-657
-
(2002)
Nat Cell Biol
, vol.4
, pp. 648-657
-
-
Inoki, K.1
Li, Y.2
Zhu, T.3
-
8
-
-
0037020044
-
Identification of TOR signaling complexes: More TORC for the cell growth engine
-
Abraham T. Identification of TOR signaling complexes: More TORC for the cell growth engine. Cell 111 (2002) 9-12
-
(2002)
Cell
, vol.111
, pp. 9-12
-
-
Abraham, T.1
-
9
-
-
5144228549
-
High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence
-
Ayala G., Thompson T., Yang G., et al. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 10 (2004) 6572-6578
-
(2004)
Clin Cancer Res
, vol.10
, pp. 6572-6578
-
-
Ayala, G.1
Thompson, T.2
Yang, G.3
-
10
-
-
3442891477
-
Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer
-
Kreisberg J.I., Malik S.N., Prihoda T.J., et al. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 64 (2004) 5232-5236
-
(2004)
Cancer Res
, vol.64
, pp. 5232-5236
-
-
Kreisberg, J.I.1
Malik, S.N.2
Prihoda, T.J.3
-
11
-
-
4344602002
-
The biology and clinical relevance of the PTEN tumor suppressor pathway
-
Sansal I., and Sellers W.R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22 (2004) 2954-2963
-
(2004)
J Clin Oncol
, vol.22
, pp. 2954-2963
-
-
Sansal, I.1
Sellers, W.R.2
-
12
-
-
0033957661
-
The PTEN tumor suppressor protein: An antagonist of phosphoinositide 3-kinase signaling
-
Vazquez F., and Sellers W.R. The PTEN tumor suppressor protein: An antagonist of phosphoinositide 3-kinase signaling. Biochim Biophys Acta 1470 (2000) M21-M35
-
(2000)
Biochim Biophys Acta
, vol.1470
-
-
Vazquez, F.1
Sellers, W.R.2
-
13
-
-
3342895823
-
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton
-
Sarbassov D.D., Ali S.M., Kim D.H., et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14 (2004) 1296-1302
-
(2004)
Curr Biol
, vol.14
, pp. 1296-1302
-
-
Sarbassov, D.D.1
Ali, S.M.2
Kim, D.H.3
-
14
-
-
13844312400
-
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
-
Sarbassov D.D., Guertin D.A., Ali S.M., et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (2005) 1098-1101
-
(2005)
Science
, vol.307
, pp. 1098-1101
-
-
Sarbassov, D.D.1
Guertin, D.A.2
Ali, S.M.3
-
15
-
-
0026485002
-
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
-
Shweiki D., Itin A., Soffer D., et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359 (1992) 843-845
-
(1992)
Nature
, vol.359
, pp. 843-845
-
-
Shweiki, D.1
Itin, A.2
Soffer, D.3
-
16
-
-
0036000028
-
Hypoxia-inducible factor-1alpha mRNA contains an internal ribosome entry site that allows efficient translation during normoxia and hypoxia
-
Lang K.J., Kappel A., and Goodall G.J. Hypoxia-inducible factor-1alpha mRNA contains an internal ribosome entry site that allows efficient translation during normoxia and hypoxia. Mol Biol Cell 13 (2002) 1792-1801
-
(2002)
Mol Biol Cell
, vol.13
, pp. 1792-1801
-
-
Lang, K.J.1
Kappel, A.2
Goodall, G.J.3
-
17
-
-
34547134517
-
Hypoxia-inducible factor 1α is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif
-
Land S.C., and Tee A.R. Hypoxia-inducible factor 1α is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem 282 (2007) 20534-20543
-
(2007)
J Biol Chem
, vol.282
, pp. 20534-20543
-
-
Land, S.C.1
Tee, A.R.2
-
18
-
-
0027535132
-
Rapamycin-induced inhibition of p34cdc2 kinase activation is associated with G1/S-phase growth arrest in T lymphocytes
-
Morice W.G., Brunn G.J., Wiederrecht G., et al. Rapamycin-induced inhibition of p34cdc2 kinase activation is associated with G1/S-phase growth arrest in T lymphocytes. J Biol Chem 268 (1993) 3734-3738
-
(1993)
J Biol Chem
, vol.268
, pp. 3734-3738
-
-
Morice, W.G.1
Brunn, G.J.2
Wiederrecht, G.3
-
19
-
-
7944223834
-
Targeting the mammalian target of rapamycin (mTOR): A new approach to treating cancer
-
Chan S. Targeting the mammalian target of rapamycin (mTOR): A new approach to treating cancer. Br J Cancer 91 (2004) 1420-1424
-
(2004)
Br J Cancer
, vol.91
, pp. 1420-1424
-
-
Chan, S.1
-
20
-
-
0030021524
-
TOR controls translation initiation and early G1 progression in yeast
-
Barbet N.C., Schneider U., Helliwell S.B., et al. TOR controls translation initiation and early G1 progression in yeast. Mol Biol Cell 7 (1996) 25-42
-
(1996)
Mol Biol Cell
, vol.7
, pp. 25-42
-
-
Barbet, N.C.1
Schneider, U.2
Helliwell, S.B.3
-
21
-
-
0038481707
-
Current strategies in the management of hormone refractory prostate cancer
-
Martel C.L., Gumerlock P.H., Meyers F.J., et al. Current strategies in the management of hormone refractory prostate cancer. Cancer Treat Rev 29 (2003) 171-187
-
(2003)
Cancer Treat Rev
, vol.29
, pp. 171-187
-
-
Martel, C.L.1
Gumerlock, P.H.2
Meyers, F.J.3
-
22
-
-
0031770827
-
Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor I
-
Kulik G., and Weber M.J. Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor I. Mol Cell Biol 18 (1998) 6711-6718
-
(1998)
Mol Cell Biol
, vol.18
, pp. 6711-6718
-
-
Kulik, G.1
Weber, M.J.2
-
23
-
-
33746794674
-
Expression of mTOR signaling pathway markers in prostate cancer progression
-
Kremer C.L., Klein R.R., Mendelson J., et al. Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 66 (2006) 1203-1212
-
(2006)
Prostate
, vol.66
, pp. 1203-1212
-
-
Kremer, C.L.1
Klein, R.R.2
Mendelson, J.3
-
24
-
-
0034687688
-
Cytoplasmic-nuclear shuttling of FKBP12-rapamycin-associated protein is involved in rapamycin-sensitive signaling and translation initiation
-
Kim J.E., and Chen J. Cytoplasmic-nuclear shuttling of FKBP12-rapamycin-associated protein is involved in rapamycin-sensitive signaling and translation initiation. Proc Natl Acad Sci USA 97 (2000) 14340-14345
-
(2000)
Proc Natl Acad Sci USA
, vol.97
, pp. 14340-14345
-
-
Kim, J.E.1
Chen, J.2
-
26
-
-
16844371494
-
Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts
-
Wu L., Birle D.C., and Tannock I.F. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 65 (2005) 2825-2831
-
(2005)
Cancer Res
, vol.65
, pp. 2825-2831
-
-
Wu, L.1
Birle, D.C.2
Tannock, I.F.3
-
27
-
-
58149233953
-
Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival
-
Wang Y., Mikhailova M., Bose S., et al. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene 27 (2008) 7106-7117
-
(2008)
Oncogene
, vol.27
, pp. 7106-7117
-
-
Wang, Y.1
Mikhailova, M.2
Bose, S.3
-
28
-
-
33749254070
-
Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer
-
Gao H., Outang X., Banach-Petrosky W.A., et al. Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci USA 103 (2006) 14477-14482
-
(2006)
Proc Natl Acad Sci USA
, vol.103
, pp. 14477-14482
-
-
Gao, H.1
Outang, X.2
Banach-Petrosky, W.A.3
-
29
-
-
0141927222
-
Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer
-
Gao N., Zhang Z., Jiang B.H., et al. Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun 310 (2003) 1124-1132
-
(2003)
Biochem Biophys Res Commun
, vol.310
, pp. 1124-1132
-
-
Gao, N.1
Zhang, Z.2
Jiang, B.H.3
-
30
-
-
16244363070
-
Functions and regulation of transforming growth factor-beta (TGF-β) in the prostate
-
Danielpour D. Functions and regulation of transforming growth factor-beta (TGF-β) in the prostate. Eur J Cancer 41 (2005) 846-857
-
(2005)
Eur J Cancer
, vol.41
, pp. 846-857
-
-
Danielpour, D.1
-
31
-
-
0034533657
-
Signaling of transforming growth factor-β family members through SMAD proteins
-
Itoh S., Jtoh F., Goumans M.J., et al. Signaling of transforming growth factor-β family members through SMAD proteins. Eur J Biochem 267 (2000) 6954-6967
-
(2000)
Eur J Biochem
, vol.267
, pp. 6954-6967
-
-
Itoh, S.1
Jtoh, F.2
Goumans, M.J.3
-
32
-
-
0034604110
-
Role of transforming growth factor-β in human disease
-
Blobe G.C., Schiemann W.P., and Lodish H.F. Role of transforming growth factor-β in human disease. N Engl J Med 342 (2000) 1350-1358
-
(2000)
N Engl J Med
, vol.342
, pp. 1350-1358
-
-
Blobe, G.C.1
Schiemann, W.P.2
Lodish, H.F.3
-
33
-
-
0027421280
-
Resistance to inhibition of cell growth by transforming growth factor-β and its role in oncogenesis
-
Fynan T.M., and Reiss M. Resistance to inhibition of cell growth by transforming growth factor-β and its role in oncogenesis. Crit Rev Oncog 4 (1993) 493-540
-
(1993)
Crit Rev Oncog
, vol.4
, pp. 493-540
-
-
Fynan, T.M.1
Reiss, M.2
-
34
-
-
0030183051
-
Tumor suppressor activity of the TGF-β pathway in human cancers
-
Markowitz S.D., and Roberts A.B. Tumor suppressor activity of the TGF-β pathway in human cancers. Cytokine Growth Factor Rev 7 (1996) 93-102
-
(1996)
Cytokine Growth Factor Rev
, vol.7
, pp. 93-102
-
-
Markowitz, S.D.1
Roberts, A.B.2
-
35
-
-
0037293657
-
Rapamycin induces Smad activity in prostate cancer cell lines
-
van der Poel H.G., Hanrahan C., Zhong H., et al. Rapamycin induces Smad activity in prostate cancer cell lines. Urol Res 30 (2003) 380-386
-
(2003)
Urol Res
, vol.30
, pp. 380-386
-
-
van der Poel, H.G.1
Hanrahan, C.2
Zhong, H.3
-
36
-
-
4544262684
-
Mammalian target of rapamycin and 3-phosphatidylinositol 3-kinase pathway inhibition enhances growth inhibition of transforming growth factor-β1 in prostate cancer cells
-
van der Poel H.G. Mammalian target of rapamycin and 3-phosphatidylinositol 3-kinase pathway inhibition enhances growth inhibition of transforming growth factor-β1 in prostate cancer cells. J Urol 172 4 Pt 1 (2004) 1333-1337
-
(2004)
J Urol
, vol.172
, Issue.4 PART 1
, pp. 1333-1337
-
-
van der Poel, H.G.1
-
37
-
-
34249779568
-
Temsirolimus, interferon α, or both for advanced renal-cell carcinoma
-
Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
-
(2007)
N Engl J Med
, vol.356
, pp. 2271-2281
-
-
Hudes, G.1
Carducci, M.2
Tomczak, P.3
-
38
-
-
34548528069
-
Phase I/II trial of temsirolimus combined with interferon α for advanced renal cell carcinoma
-
Motzer R.J., Hudes G.R., Curti B.D., et al. Phase I/II trial of temsirolimus combined with interferon α for advanced renal cell carcinoma. J Clin Oncol 25 (2007) 3958-3964
-
(2007)
J Clin Oncol
, vol.25
, pp. 3958-3964
-
-
Motzer, R.J.1
Hudes, G.R.2
Curti, B.D.3
-
39
-
-
1542398693
-
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
-
Atkins M.B., Hidalgo M., Stadler W.M., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 (2004) 909-918
-
(2004)
J Clin Oncol
, vol.22
, pp. 909-918
-
-
Atkins, M.B.1
Hidalgo, M.2
Stadler, W.M.3
|